These findings underscore the need to consider defining highly clinically aggressive undifferentiated carcinoma based on core SWI/SNF‐deficiency, and to consider close follow‐up and alternative systemic treatment strategies in these cases. This evidence concerns the gene SMARCA1 and undifferentiated carcinoma.